Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer

Abstract

Nasal septum perforation in patients with cancer receiving systemic therapy is rare, and its association with bevacizumab use has described recently in the literature. Here, we report the case of a 34-year-old woman with hormone-sensitive, HER-2/neu negative, metastatic breast cancer who develope a nasal septum perforation during the treatment with paclitaxel and bevacizumab.

A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer

“…It has become known about unique adverse events such as gastrointestinal perforation and fistula formation; however, little is known about a rare adverse event of nasal septal perforation. The frequency in other cancer types is estimated to be around 0.5% (0.2% for ovarian cancer, 0.3% for maintenance therapy, 1.0% for colorectal cancer and 7.14% for breast cancer) (Table 2), 3,9–20 but as far as we know there are no reports of cervical cancer. Our case is considered to be the first report of perforation of the nasal septum caused by bevacizumab in a patient with cervical cancer.…”

Perforation of the Nasal Septum in a Colorectal Cancer Patient Treated With Aflibercept: A Case Report

“…A literature search of PubMed found few case reports published of septum perforation with bevacizumab [7][8][9][10][11][12][13][14][15][16]. The scientific literature regarding the incidence of this complication is scarce.…”